Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer

Kurt Miller1 · Günther G. Steger2 · Daniela Niepel3 · Diana Lüftner4

Received: 31 October 2017 / Revised: 20 February 2018 / Accepted: 19 March 2018 / Published online: 9 July 2018
© The Author(s) 2018. This article is published with open access

Abstract

Background Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients are also at risk of bone loss due to androgen deprivation therapy (ADT), which can be compounded in elderly patients with reduced bone density. It is essential, therefore, that aspects of bone health and therapies able to prevent the occurrence of SREs are considered throughout the clinical course of prostate cancer.

Methods We reviewed the literature regarding the molecular mechanisms underpinning bone lesion formation, the modes of action of therapies that prevent SREs, and the efficacy and safety of these therapies in patients with hormone-sensitive or castration-resistant prostate cancer (CRPC).

Results Therapies such as denosumab (a RANKL inhibitor) and zoledronic acid (a bisphosphonate) were indicated for prevention of SREs. Radium-223 dichloride also has proven efficacy in delaying symptomatic SREs, as well as in improving overall survival through effects on bone metastases. Before development of bone metastases, low-dose denosumab may also be used for treatment of ADT-associated bone loss. Denosumab may also have the potential to delay bone metastases development in patients with CRPC, although this is not currently an approved indication. The safety profile of therapies to prevent SREs should be considered. This review consolidates the available evidence on use of denosumab and bisphosphonates in prostate cancer, differentiated by hormone-sensitive and castration-resistant disease.

Conclusions There is convincing evidence to support the use of denosumab and bisphosphonates to maintain bone health in patients with prostate cancer. Clinicians should be mindful of the adverse event risk profile of these therapies.

Introduction

The skeleton is a common site of metastases in prostate cancer; indeed, more than 90% of patients with metastatic, castration-resistant prostate cancer (mCRPC) have evidence of bone metastases [1, 2]. The factors that determine the location of secondary tumors are complex; however, blood flow patterns and cell signaling pathways, such as the C-X-C motif chemokine 12–C-X-C chemokine receptor type 4 axis, are both influential [3, 4]. The propensity for bone metastases also reflects the favorable microenvironment that results from release of growth factors during bone resorption [5–7].

Patients with bone metastases may develop skeletal complications, known as skeletal-related events (SREs), which include pathologic fracture, radiation, or surgery to bone and spinal cord compression [8]. Spinal cord compression is of particular concern in prostate cancer given the high frequency of metastases at this site [2, 9] and its debilitating consequences, which can include paralysis [8, 9]. However, pathologic fracture and radiation to bone (used to treat bone pain) are also common in this population owing to bone instability in osteoblastic metastatic lesions.
Patients with bone metastases can experience multiple SREs each year [12], placing a considerable burden on patients and healthcare systems [11, 13]. SREs are associated with increased mortality, substantial pain, and reduced quality of life (QoL) [13–17].

Further complicating the preservation of bone health in prostate cancer is the fact that androgen deprivation therapy (ADT) causes considerable reductions in serum testosterone and estradiol levels, leading to cancer treatment-induced bone loss (CTIBL) and an increased fracture risk proportional to the treatment duration [18, 19]. It is important to bear in mind that patients with prostate cancer are typically elderly, with impaired bone strength before ADT is initiated. For example, a study of 348 men (median age 55.4 years) found that prevalence of osteoporosis in those aged over 50 years was ~19%, and, in a study of 618 men with newly diagnosed advanced prostate cancer starting ADT treatment (mean patient age 73 years), 80% had abnormal bone mineral density (BMD) at baseline [20, 21].

The maintenance of bone health is therefore central to all stages of prostate cancer treatment. The management of patients with bone metastases focuses on preventing SREs, palliating pain, and maintaining QoL [22]. The inhibitors of bone resorption, zoledronic acid (a bisphosphonate) and denosumab (a receptor activator of nuclear factor-kappaB [23] ligand [RANKL] inhibitor), are approved for SRE prevention in patients with solid tumors metastatic to bone [24, 25]. In addition, the bone-seeking radiopharmaceutical radium-223 dichloride (radium-223) has been approved for treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases [26]. Denosumab is also approved for protecting against ADT-induced bone loss (at a lower dose than that indicated for bone metastases) [25]. Denosumab and bisphosphonates have been investigated in other roles, such as in bone metastases prevention [27, 28]. Understanding the role that denosumab and bisphosphonates may have at various stages is imperative to ensure that patients with prostate cancer receive optimal care.

This review summarizes the molecular mechanisms underpinning bone lesion formation, together with the modes of action through which bisphosphonates and denosumab prevent SREs. Bone health in patients with hormone-sensitive prostate cancer and in those with castrate-resistant disease is discussed. Safety considerations when using agents to prevent SREs are surveyed, and an overview is given of ways in which use of bisphosphonates or denosumab can be optimized in current clinical practice.

**Molecular basis of CTIBL and bone metastasis**

In healthy adults, bone is in a perpetual state of remodeling, a process that is essential to preserve structural integrity and minimize the risk of fragility fractures [29]. Bone remodeling involves several cell types, including osteoclasts (cells that resorb bone), osteoblasts (cells that produce and secrete osteocalcin and calcified matrix) and osteocytes (cells that regulate osteoclast development); bone homeostasis relies on precise signaling between the three cell types [3].

Reductions in estrogen levels, induced by ADT, lead to dysregulation of bone remodeling through the parathyroid-mediated activation of osteoclasts [30, 31]. Circulating tumor cells that settle in bone also alter the delicate signaling balance between osteoblasts, osteoclasts, and osteocytes [3].

**Mechanisms of action of bisphosphonates and denosumab**

Nitrogen-containing bisphosphonates are small molecules that dock in hydroxyapatite binding sites on bone surfaces. When osteoclasts begin to resorb bisphosphate-impregnated bone, bisphosphonates are liberated and bind to farnesyl pyrophosphate synthase inside the osteoclasts, ultimately leading to apoptosis [24, 42, 43]. Denosumab is a fully humanized monoclonal antibody, which has a different mechanism of action to bisphosphonates; it targets and binds to RANKL, preventing activation of RANK on the surface of osteoclasts. Inhibition of the RANKL–RANK interaction impedes osteoclast formation, function, and survival, thereby decreasing bone resorption [34].

**Bone health in patients with hormone-sensitive prostate cancer**

In early-stage prostate cancer, ADT is the mainstay of therapy. Treatment guidelines, such as those from the European Society for Medical Oncology (ESMO),
recommend ADT (e.g., gonadotropin-releasing hormone [GnRH] agonists or antagonists) alongside surgical and radiotherapy options in the management of locally advanced prostate cancer, as well as high-risk localized prostate cancer [44]. ADT is also recommended for metastatic, hormone-sensitive prostate cancer (mHSPC) [44].

ADT causes CTIBL in patients with prostate cancer [45]. Reductions in BMD of 5–10% are typical in the first year after ADT initiation [18]. This translates into an increased fracture risk that is proportional to ADT duration [19]. In a 7-year cohort study using data from a United States (US) claims database, clinical fractures in men with GnRH-agonist-treated, non-metastatic prostate cancer increased by 21% relative to matched, untreated patients [46]. Although some additional fractures may have been related to bone metastases, a longer treatment duration conferred a greater fracture risk [46]. In a New Zealand population-based cohort study, ADT was associated with a significantly increased risk of any fracture and hip fracture requiring hospitalization. Data from Canada, China, and the United Kingdom (UK) have also demonstrated an increased fracture risk following ADT [46–49].

Denosumab and bisphosphonates may also promote bone health in non-metastatic HSPC. Significant improvements in BMD have been reported in patients receiving additional zoledronic acid, alendronate or risendronate vs placebo [50–52], and zoledronic acid and pamidronate both prevented BMD loss in ADT-treated patients (Fig. 1) [53, 54]. However, none of the bisphosphonates are approved for CTIBL treatment [29]. In contrast, the RANKL inhibitor denosumab is indicated for prevention of ADT-associated bone loss in men with increased fracture risk [55]. In a placebo-controlled study of denosumab given at the licensed dose of 60 mg subcutaneously (SC) every 6 months to 1468 men receiving ADT for non-metastatic HSPC, 36 months of denosumab treatment led to increased BMD compared with baseline at all sites and a reduction in the incidence of new vertebral fractures (1.5% with denosumab vs 3.9% with placebo; relative risk: 0.38; 95% confidence interval [CI]: 0.19–0.78; p = 0.006) [56]. Beneficial effects of denosumab over placebo were also observed in patient subgroups defined by age, duration and type of previous ADT, BMD T-score, weight, body mass index, bone turnover marker levels, and number of prevalent vertebral fractures [57].

Both high-dose denosumab and high-dose zoledronic acid, are indicated for prevention of SREs in adults with bone metastases from prostate cancer [24, 25]. Although these indications include mHSPC, regulatory trials for both agents were conducted in mCRPC, and effects in HSPC...
have not been fully investigated. Early use of intravenous (IV) zoledronic acid 4 mg every 4 weeks, as an ADT adjunct to prevent SREs in mHSPC, was evaluated in the phase 3 Cancer and Leukaemia Group B (CALGB) 90202 study; however, it was terminated early because no beneficial effect on time to first SRE was observed with zoledronic acid [58]. Nonetheless, it has been suggested that further data analysis for patients with decreased baseline BMD could help to evaluate whether some subgroups may benefit from zoledronic acid in the hormone-sensitive stage [59].

Another aspect to be considered at the hormone-sensitive stage is the potential for therapeutic intervention to delay disease progression. The Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases (ZAPCA) trial in men with treatment-naive, metastatic prostate cancer indicated that zoledronic acid and ADT may delay development of castration resistance in a subset with low baseline, prostate-specific antigen values [60]. Data from a preclinical study in hypogonadal mice inoculated with human prostate cancer cell lines suggested that androgen depletion accelerated bone metastasis. Of note, bone metastasis reduced when the mice received zoledronic acid [32]. Based on these observations, denosumab and bisphosphonates might have been expected to have a positive survival effect in HSPC. However, the controlled, multiple-arm Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) study showed that, for 2962 patients with HSPC with and without metastases receiving standard of care (ADT plus optional radiotherapy), addition of zoledronic acid (4 mg every 3–4 weeks) and docetaxel, or zoledronic acid alone, showed no improvement in survival compared with docetaxel and standard of care [61]. Similarly, addition of zoledronic acid and celecoxib to standard of care also failed to improve survival significantly, although it did improve survival in a pre-planned subgroup analysis of men with metastatic cancer [62]. The lack of survival impact of zoledronic acid added to standard of care was corroborated by a meta-analysis of studies in HSPC [63]. Findings from the Medical Research Council (MRC) PR04 and PR05 studies of clodronate and ADT showed some overall survival benefit in patients with metastases compared with placebo (hazard ratio [HR]: 0.77; 95% CI: 0.60–0.98; \( p = 0.032 \)), but not in those without metastases (HR: 1.12; 95% CI: 0.89–1.42; \( p = 0.94 \)) [64]. The PR05 study showed no significant bone progression-free survival benefit in patients with metastases (Fig. 1) [65]. This lack of benefit could suggest that other mechanisms contribute to bone metastases development. For example, research suggests that human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) are upregulated in response to ADT; [66, 67] in addition, a recent study demonstrated that EGFR promotes the survival of prostatic tumor infiltrating cells and circulating tumor cells that metastasize to bone, and that HER2 supports the growth of prostate cancer cells once they are established at the site of metastasis [68]. Levels of RANK and RANKL expression have been shown to be higher in aggressive metastatic prostate cancer cells than that in cells removed from primary tumors, lending support to a hypothesis that osteoclast mediated bone resorption my stimulate colonization and progression of metastases in bone [69, 70]. It is possible that treatment regimens may need to target multiple mechanisms to increase survival effectively.

**Bone health in patients with castrate-resistant prostate cancer**

Patients with HSPC might expect to progress to CRPC ~2–3 years after ADT initiation [71]; however, most patients with recurrent or metastatic HSPC who are treated with ADT progress more quickly (median 18–24 months) [72, 73]. SREs are associated with increased mortality in CRPC and bone metastases [74], and bone-related parameters are good overall survival prognostic variables [75]. Both zoledronic acid (4 mg IV every 3–4 weeks) and denosumab (120 mg SC every 4 weeks) are indicated for SRE prevention in patients with CRPC and existing bone metastases [12, 29, 76, 77]. In a placebo-controlled study of 643 men with CRPC and bone metastases, zoledronic acid treatment led to fewer SREs (38% vs 49% with placebo; \( p = 0.028 \)) and reduced the overall skeletal complications risk by 36% [12]. Treatment with denosumab has shown superiority to zoledronic acid for time to first SRE, and to second and subsequent SREs, in a phase 3, placebo-controlled, double-blind study of 1904 men with CRPC and bone metastases [77]. Time to first SRE was extended from 17.1 to 20.7 months (HR: 0.82; 95% CI: 0.71–0.95; \( p = 0.008 \) for superiority). Second and subsequent SREs were also delayed, resulting in an 18% reduction in cumulative SREs [77]. In addition, a post hoc analysis has shown that denosumab reduced the risk of symptomatic skeletal events (SSEs) compared with zoledronic acid [78].

Skeletal pain is a complication of bone metastases that has a substantial impact on QoL [17] and may respond poorly to treatment. In addition to direct effects on bone health, denosumab and bisphosphonate treatment can ameliorate bone pain [13, 79]. In a pooled analysis of data from three phase 3 studies in patients with bone metastases from CRPC, breast cancer and other solid tumors, denosumab was superior to zoledronic acid with regard to pain improvement and interference [13, 79]. Denosumab treatment delayed the onset of moderate/severe pain by 1.8 months (median: 6.5 vs 4.7 months; HR: 0.83; 95% CI:
0.76–0.92; \( p < 0.001 \)) and clinically meaningful increases in overall pain interference by 2.6 months (median: 10.3 vs 7.7 months; HR: 0.83; 95% CI: 0.75–0.92; \( p < 0.001 \)) compared with zoledronic acid. Fewer denosumab-treated patients required strong opioids or reported worsening of clinically meaningful health-related QoL compared with patients treated with zoledronic acid [79].

In addition to denosumab and zoledronic acid, a different class of agent has emerged. Radium-223 is a calcium mimetic that binds preferentially to newly formed bone in metastases; [80] its benefits in mCRPC were demonstrated in the phase 3 Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial, in which it was compared with placebo when added to standard of care.1 The trial was terminated early after a planned interim analysis demonstrated a significant overall survival benefit of radium-223, which was the primary endpoint.1 Updated analyses demonstrated continued survival improvement (14.9 vs 11.3 months with radium-223 vs placebo, respectively; HR: 0.70; \(^{95\%\ CI: \ 0.58–0.83; \ p < 0.001}\)).1 Radium-223 also significantly prolonged time to first SSE compared with placebo (median: 15.6 vs 9.8 months; HR: 0.66; 95% CI: 0.52–0.83; \( p < 0.001 \)).1 The survival benefits of radium-223 have been corroborated by results of a study of patients with mCRPC and symptomatic or asymptomatic bone metastases enrolled in an early access program, in which median overall survival was 16 months [81]. Significant pain reduction (\( p = 0.035 \)) was demonstrated within 2 weeks in a phase 2 trial, with a dose-dependent pain response observed in up to 71% of patients after 8 weeks [82].

It has been suggested that denosumab and bisphosphonates can prevent development of bone metastases in patients with CRPC; however, this has not been demonstrated consistently. Zoledronic acid therapy, for example, has failed to result in any clear bone metastases prevention in both HSPC and CRPC studies [28]. In the Zometa European Study (ZEUS) of zoledronic acid (4 mg every 3 months) in 1433 men with high risk, localized prostate cancer, no significant improvement in bone metastasis-free survival was observed after a median follow-up of 4.8 years (Fig. 1) [28]. However, in a phase 3, double-blind, randomized, placebo-controlled study of men with non-metastatic CRPC at high risk of bone metastases, denosumab (120 mg every 4 weeks) significantly increased bone metastasis-free survival (by a median of 4.2 months vs placebo; HR: 0.85; 95% CI: 0.73–0.98; \( p = 0.028 \)) and delayed time to first bone metastases (33.2 vs 29.5 months with placebo; HR: 0.84; 95% CI: 0.71–0.98; \( p = 0.032 \)). Overall survival did not differ between the groups [27]. Nonetheless, denosumab is not indicated in patients without bone metastases, possibly because the difference in bone metastasis-free survival was not deemed to be clinically meaningful by regulators [83]. Further studies may be warranted to determine effects of denosumab and bisphosphonate on prevention of bone metastases in CRPC; this is particularly relevant for patients with short prostate-specific antigen (PSA) doubling times, as a study has demonstrated that PSA velocity is an independent predictor of time to first bone metastasis [27, 28, 59, 84]. In addition, more evidence is required to determine whether delaying bone metastases can reduce SREs. This information will help to inform the benefit–risk profile of long-term treatment with denosumab and bisphosphonates.

**Key safety considerations for denosumab and bisphosphonates**

Denosumab and bisphosphonate safety profiles have been described previously and are generally acceptable [12, 76, 77, 85]. However, adverse events should be considered when assessing the benefit–risk ratio, particularly given the likelihood that denosumab and bisphosphonates will be used for longer in clinical practice than has been investigated historically [59].

Denosumab and bisphosphonates inhibit osteoclastic bone resorption and reduce skeletal calcium release; consequently, they are associated with a hypocalcemia risk [86]. In the comparative study of denosumab 120 mg and zoledronic acid 4 mg every 4 weeks, hypocalcemia occurred in 13% and 6% of patients, respectively [77]. The higher hypocalcemia incidence with denosumab vs zoledronic acid was consistent with its greater antiresorptive effect [25, 77, 86]. Hypocalcemia appears to occur most often during the initial stages of therapy, but stabilizes thereafter and does not increase with exposure duration [86]. Label guidelines for zoledronic acid and denosumab advise calcium and vitamin D supplementation, pre-treatment low serum vitamin D and calcium correction, and serum calcium monitoring during treatment [24, 25, 55].

Denosumab and bisphosphonates have also been associated with an elevated osteonecrosis of the jaw (ONJ) risk, although it was not recognized as an adverse event of interest at the time of the zoledronic acid initial studies [76]. A small proportion of patients with prostate cancer reported this adverse event in the comparative study (denosumab, 2.3%; zoledronic acid, 1.3%; \( p = 0.09 \)) [77]. The incidence of ONJ increases with time, and is more common in patients with poor oral health or a tooth extraction history [87]. Recent safety findings from the comparative study open-label extension showed an ONJ incidence (unadjusted for exposure) of 8.2% for patients with metastatic prostate cancer who received denosumab (120 mg every 4 weeks); cumulative ONJ incidence was 3.8% when given for up to 5.6 years [85]. For patients who initially received zoledronic acid (4 mg every 4 weeks) and then switched to denosumab, ONJ incidence was 5.9% over 5 years; cumulative incidence was 2.2% over a period of up to 3.4 years [85]. In the
overall study analysis (patients with breast or prostate cancers), patient-year adjusted incidence of confirmed ONJ was 1.1% during the first treatment year, 3.7% during the second and 4.6% per year thereafter [88]. To reduce ONJ risk, ESMO guidelines recommend preventative dental measures before starting treatment, and good oral hygiene maintenance and invasive dental procedure avoidance during therapy [29].

Zoledronic acid is not metabolized and is excreted unchanged via the kidneys. It is not indicated for patients with severe renal impairment (creatinine clearance < 30 mL/min); also, it should be used with caution in mild-to-moderate renal impairment and may require dose adjustment [24]. For denosumab, renal monitoring and dose adjustments are not needed, including in severe renal impairment [25, 89]. However, individuals with severe renal impairment are at risk of hypocalcemia and should be monitored closely [25].

Radiopharmaceutical agents have historically been associated with a myelosuppression risk [90]. Radium-223, however, offers highly localized tissue destruction with low levels of myelosuppression [80]. The ALSYMPCA trial provided evidence that radium-223 might be better tolerated than older generation radiopharmaceuticals; incidences of grades 3 and 4 anemia, neutropenia and thrombocytopenia were minimal (13%, 3.1%, and 6.1%, respectively) [1].

Current practice with denosumab and bisphosphonates in prostate cancer

Clearly, proactive management of bone health is important in prostate cancer. In clinical practice, however, many patients do not undergo bone density assessment. For instance, in a Canadian survey of 156 prostate cancer specialists, only 32.5% reported routinely measuring BMD before starting ADT and 36.6% did so 1–2 years after treatment initiation [91]. This is probably a barrier to appropriate prescription of denosumab and bisphosphonates in prostate cancer management.

There is some suggestion that denosumab and bisphosphonate prescribing behavior may vary according to the prescriber’s specialty. An analysis of denosumab and bisphosphonate real-world treatment patterns across six European Union countries was conducted using data from 1971 patients with prostate cancer and bone metastases [92]. This revealed that patients were more likely to receive denosumab and bisphosphonates if treated by an oncologist rather than a urologist (78% vs 60%, respectively), and treatment was more likely to be initiated early (56% vs 43%, respectively) [92]. Low rates of bisphosphonate treatment, and long delays between diagnosing bone metastases and initiating therapy, have also been reported in US community-based urology group practices [93].

Optimizing the use of denosumab and bisphosphonates in clinical practice

Evidence suggests that denosumab and bisphosphonates may promote bone health in patients with prostate cancer. However, integration of these agents into disease management is constrained by their licensed indications and is complicated by the evolving treatment landscape. As with any clinical intervention, it is important to evaluate the benefit–risk profile when considering the role of these agents. For example, while the risk of hypocalcemia peaks early, ONJ incidence increases with treatment duration [86, 87]. This safety profile must be considered when initiating denosumab and bisphosphonate therapy, in order not to restrict their availability later on when patients are at a higher risk of SREs. The point at which denosumab and bisphosphonates therapy should be initiated, and their doses subsequently increased, remains unclear. A lack of data exists that compares high-dose denosumab and bisphosphonate efficacy for SRE prevention in HSPC, and also in early- vs late-stage mCRPC; such data would help to determine the point at which treatment should be started.

Such uncertainties regarding initiation and dosing of these agents are common to all cancers associated with bone metastases; therefore, ESMO has produced guidelines on bone health in patients with cancer [29]. These guidelines recommend that denosumab or zoledronic acid therapy ‘should be’ commenced on diagnosing bone metastases, and ‘should’ continue indefinitely and throughout the disease course [29]; however, evidence suggests this may not happen in clinical practice [94]. Denosumab and bisphosphonates have a role in treating CTIBL in men receiving ADT [57, 95, 96], and their use is ‘generally recommended’ by the ESMO guidelines [29], although only denosumab is licensed for this indication [55]. The ESMO guidelines also recognize that denosumab has been shown to delay bone metastases in CRPC [27, 29], and ‘generally recommend’ its use [29], although denosumab is not licensed for this indication [25]. No recommendations relating to use of radium-223 feature in this guidance [29].

In addition to the general ESMO guidelines on bone health in cancer [29], recommendations for use of denosumab and bisphosphonates in patients with prostate cancer are available in a number of clinical practice guidelines [29, 39, 40, 44, 97]. However, recommendations across these guidelines are inconsistent, which may suggest a need for more data to inform when to use denosumab and bisphosphonates in mCRPC. For instance, the ESMO prostate cancer guidelines recommend denosumab or zoledronic acid for patients with bone metastases from CRPC at high risk of clinically significant SREs [44], which is inconsistent with the aforementioned general ESMO bone health in cancer guideline recommendation for use of these
agents in all patients with bone metastases [29]. The ESMO prostate cancer guidelines do not make recommendations regarding optimal treatment duration and dosing. They advise that men receiving long-term ADT should be monitored for side effects, including osteoporosis, although they do not make recommendations regarding use of denosumab or bisphosphonates in patients receiving ADT [44]. Radium-223 is supported as a first- or second-line mCRPC treatment option [44].

The St Gallen Advanced Prostate Cancer Consensus Conference guidelines recommend that the majority of men with CRPC and bone metastases should receive an osteoclast-targeted agent for SRE and SSE prevention [39]. However, the optimal time to initiate treatment, and treatment intensity and duration are unclear in these guidelines [39]. Radium-223 is not supported for routine use as a first-line treatment in patients with mCRPC [39].

The European Association of Urology prostate cancer guidelines recommend that denosumab or zoledronic acid may be offered to men with CRPC and skeletal metastases, along with calcium and vitamin D supplementation, to prevent osseous complications [40]. These guidelines also state that, for patients receiving ADT, preventative treatment with low-dose bisphosphonates or denosumab could be considered in individuals at risk of fracture. A dual-energy, X-ray absorptiometry scan is recommended for patients initiating ADT; bisphosphonates or denosumab should be considered for those with a T-score of less than −2.5 [40]. They also highlight the survival benefit reported for radium-223 in CRPC with symptomatic bone metastases, in those patients ineligible for, or whose disease is progressing after, docetaxel treatment [40].

An International Society of Geriatric Oncology (SIOG) position paper has highlighted the need to focus on bone health among elderly men with prostate cancer, owing in part to the steady decline in BMD that occurs with aging [97]. The paper indicates that, despite the value of agents such as denosumab and bisphosphonates in elderly patients with cancer, they are typically underutilized. The SIOG recommends that men aged over [75] years treated with ADT for prostate cancer should receive denosumab and bisphosphonates at doses used to prevent osteoporosis, and supports treatment initiation as soon as bone metastases are diagnosed to delay SREs and reduce complications. With regard to safety, consideration is needed of age-associated increases in hypocalcemia, vitamin D deficiency and dental disease risk [97]. Treatment choice may also be guided by an elderly patient’s renal function, with denosumab requiring no dose adjustment in cases of renal impairment [25].

The Cancer Care Ontario guidelines state that use of denosumab at a dose of [60] mg every 6 months should be considered to reduce fracture risk in men receiving ADT with non-metastatic prostate cancer at high risk of fracture. Denosumab at a dose of 120 mg every 4 weeks is recommended to prevent or delay SREs in patients with non-symptomatic mCRPC [98]. Bisphosphonates, at doses indicated for metastatic bone disease, are recommended for the same purpose in those with mildly symptomatic or asymptomatic CRPC. No medication is recommended to prevent development of bone metastases in patients with non-metastatic prostate cancer [98]. The guidelines suggest that radium-223 should be considered for the reduction of SSEs, to improve health-related QoL and to extend overall survival in patients with symptomatic mCRPC [98].

The benefits of denosumab and bisphosphonates in patients with prostate cancer become increasingly apparent as the disease progresses to CRPC and metastasizes to bone [59]. The role of these agents in CRPC is influenced, however, by the impact of other treatments on bone health. New-generation hormonal agents (abiraterone and enzalutamide) are now available and their influence on bone health must be considered. Both abiraterone and enzalutamide have been shown to prevent SREs and delay pain progression in patients with mCRPC [99, 100], although it has not been established whether these benefits are mediated by the antineoplastic effects of these agents or whether there is also an effect on the interaction between tumor cells and bone [59]. Data have also suggested that adding abiraterone to ADT may also delay SSEs in hHSPC [101]. Few data are available regarding denosumab and bisphosphonate effects when used in combination with these new-generation hormonal agents. However, a post hoc analysis of data from both treatment arms of the COU-AA-302 trial of abiraterone in mCRPC has suggested improved overall survival in patients receiving concomitant denosumab, zoledronic acid or other similar agents [102]. Data were also reported from a phase 3 study of 839 patients from an early access program suggesting survival benefits from combining radium-223 with abiraterone or enzalutamide, or both, or with denosumab [81].

There are no high-quality data to guide treatment duration with high-dose denosumab or bisphosphonates in patients with bone metastases, and expert opinion is divided on this topic; [39] however, reducing the dose frequency after an initial high-dose period is practiced and has been incorporated in clinical practice guidelines. For example, the ESO (European School of Oncology)–ESMO advanced breast cancer consensus guidelines suggest that it may be a reasonable compromise to replace 4-weekly with 3-monthly IV zoledronic acid therapy after an initial 1-year period [103]. Evidence in support of this practice in prostate cancer is emerging; a recent study has suggested the non-inferiority of 12- vs 4-weekly zoledronic acid regimens with respect to preventing SREs in patients with prostate cancer metastatic to bone (and also breast cancer and multiple
myeloma) [104]. A similar trial evaluating denosumab scheduling with respect to preventing SSEs is ongoing (NCT02051218) [105].

Although there are apparent inconsistencies regarding denosumab and bisphosphonate initiation and dosing across guideline recommendations, the licensed indications of denosumab (120 mg every 4 week) and zoledronic acid (4 mg every 3–4 weeks) for prevention of SREs in adults with bone metastases from solid tumors [25], or advanced malignancies involving bone [24], respectively, do not specify the need for a SRE risk assessment or symptomatic bone metastases. These indications are informed by phase 3 trial data in which patients with current or previous objective evidence of bone metastases were treated without reference to their SRE risk [12, 27].

In addition to the benefits that might be achieved with denosumab and bisphosphonate use in prostate cancer, it is important to consider the implications of maintaining bone health on cost and healthcare resource utilization (HRU). Few studies directly examine the cost and HRU of CTIBL in prostate cancer, but it is well established that fractures secondary to osteoporosis, such as those caused by CTIBL, can result in severe pain, fatigue, functional impairment and a mortality of up to 20%, and can incur a significant cost to healthcare systems [106]. Evidence from the prospective, multinational, observational STARS study [107], and a European illness cost study [13], has illustrated the substantial cost and burden on HRU associated with SREs.

Conclusions

Denosumab and zoledronic acid, as well as radium-223, have an established role in SRE prevention in mCRPC. Evidence suggests that denosumab and bisphosphonates can also protect bone health earlier in the course of prostate cancer. Recommendations for best practice on using these agents in patients with prostate cancer are available from a number of guidelines. However, it is apparent that there is a lack of consensus—based on a paucity of supporting data—relating to the practical integration of denosumab and bisphosphonates into prostate cancer management algorithms. As for other cancers, clarification is needed with regard to the time at which denosumab and bisphosphonates should be initiated in early-stage prostate cancer, and how long patients should be treated with low-dose denosumab and bisphosphonates before switching to high-dose. More data are required to determine the relative levels of early treatment benefit and risk, which may then be reflected in product licenses. With investigations ongoing, recommendations for the optimal integration of these agents in prostate cancer management should become clearer. When considered overall, there is convincing evidence to support use of denosumab and bisphosphonates to maintain bone health in patients with cancer, provided that clinicians are also mindful of the adverse events risk profile of these agents.

Acknowledgements Writing support was provided by Sarah Griffiths, PhD of Oxford PharmaGenesis, Oxford, UK, and was funded by Amgen (Europe) GmbH. Editorial support was provided by Emma Booth, Stéphane Gamboni, and Camilla Normen of Amgen (Europe) GmbH.

Funding Writing and editorial support for this manuscript was funded by Amgen (Europe) GmbH.

Author contributions All authors conceived or designed the work that led to the submission, played an important role in interpreting the data included, revised the manuscript, and approved the final version.

Compliance with ethical standards

Conflict of interest Kurt Miller has received consultancy fees from Amgen, Astellas, Bayer, Bristol-Myers Squibb, Ferring, Janssen, Medivation, Merck, Merck Sharp & Dohme, Pfizer and Roche, and consultancy fees, and grants from Novartis. Günther Steger has received honoraria and travel support from, and has attended advisory boards for, Amgen. Daniela Niepel is an employee of Amgen and holds stock. Diana Lüftner is member of advisory boards and speaker bureaus for Amgen.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
2. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–83.
3. Gdowski AS, Ranjan A, Vishwanatha JK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res. 2017;36:38.
4. Kakhki VR, Anvari K, Sadeghi R, Mahmoudian AS, Torabian-Kakhki M. Pattern and distribution of bone metastases in common malignant tumors. Nucl Med Rev Cent East Eur. 2013;16:66–9.
5. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6:2609–17.
6. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.
Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer

7. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.
8. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243–9s.
9. Dushyanthen S, Cossigny DA, Quan GM. The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer. Cancer Growth Metastasis. 2013;6:61–80.
10. Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer. 2008;16:879–89.
11. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16:579–84.
12. Saad F, Gleason DM, Murray R, Tchekmedyan S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–82.
13. Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, et al. Cost of skeletal complications from bone metastases in six European countries. J Med Econ. 2016;19:611–8.
14. Oeefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005–7.
15. Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, et al. Amgen Europe BV. XGEVA (denosumab) summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. Accessed Oct 2017.
16. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, et al. Novartis Europharm Limited. Zometa summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002653/WC500156172.pdf. Accessed Oct 2017.
17. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25(suppl ii):124–37.
18. Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res. 2006;12:6315–6s.
19. Radocha J, Pour L, Spicka I, Scudla V, Gregora E, Frankova H, et al. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.
20. Broder MS, Gutierrez B, Cherepanov D, Linhares Y. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer. 2014;22:237–47.
21. Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.
22. Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol. 2013;9:365–74.
23. Wadhva VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104:800–5.
24. Melton LJ 3rd, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res. 1998;13:1915–23.
25. Hernandez RK, Adhia A, Wade SW, O’Connor E, Arellano J, Francis K, et al. Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clin Epidemiol. 2015;7:335–45.
26. Radocha J, Pour L, Spicka I, Scudla V, Gregora E, Frankova H, et al. Registry of monoclonal gammopathies (RMG) in the Czech Republic. Blood. 2015;126:Abstr 4514.
27. Novartis Europharm Limited. Zometa summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000336/WC500051730.pdf. Accessed Oct 2017.
28. Amgen Europe BV. XGEVA (denosumab) summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. Accessed Oct 2017.
29. Bayer AG. Xofogo summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002653/WC500156172.pdf. Accessed Oct 2017.
30. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39–46.
31. Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEU5). Eur Urol. 2015;67:482–91.
32. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25(suppl ii):124–37.
33. Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab. 2001;86:511–6.
34. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12:6213s–6s.
35. Roodman GD, Silberman R. Mechanisms of osteolytic and osteoblastic skeletal lesions. Bone Rep. 2015;4:753.
36. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.
37. Brodowicz T, Hadji P, Niepel D, Diel I. Early identification and intervention matters: a comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer. Cancer Treat Rev. 2017;61:23–34.
38. Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol. 2011;80:410–2.
39. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol. 2005;2:504–17.
40. Zhao H, Han KL, Wang YZ, Chen Y, Li HT, Zeng JL, et al. Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors. Med Sci Monit. 2011;17:CR626–33.
41. Gillessen S, Omlin A, Attard G, de Bon J, Efstatioiu E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589–604.
42. Mottet N, Bellmunt N, Briers E, van den Bergh R, Bolla M, van Casteren N et al. European Association of Urology guidelines on prostate cancer. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. Accessed Oct 2017.
43. Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30:607–13.
43. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581–9.

44. Parker C, Gillessen S, Heidenreich A, Horwich A, Committee EG. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v69–77.

45. Butoescu V, Tombal B. Practical guide to bone health in the spectrum of advanced prostate cancer. Can J Urol. 2014;21:84–92.

46. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897–903.

47. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleschner NE, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184:918–23.

48. Jefferies ER, Bahl A, Hounsome L, Eylert MF, Verne J, Persad RA, et al. Admissions to hospital due to fracture in England in patients with prostate cancer treated with androgen-deprivation therapy - do we have to worry about the hormones? BJU Int. 2016;118:416–22.

49. Wu CT, Yang YH, Chen PC, Chen MF, Chen WC. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporos Int. 2015;26:2281–90.

50. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.

51. Klotz LH, McNell YI, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol. 2013;63:927–35.

52. Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, et al. Randomized, double-blind, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2013;85:1239–45.

53. Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2014;15:1076–89.

54. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–55.

55. Amgen Europe BV. Prolia (denosumab) summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/001120/WC500093526.pdf. Accessed 2017 Oct.

56. Smith MR, Egerdie B, Hernandez Torz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55.

57. Smith MR, Saad F, Egerdie B, Szewadowski M, Tammela TL, Ke C, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009;182:2670–5.

58. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Studler W, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014;32:1143–50.

59. Todenhofer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015:2015. https://doi.org/10.1155/2015/838202.

60. Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, et al. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. Int J Clin Oncol. 2017;22:166–73.

61. James ND, Sydes MR, Clarke NW, Mason MD, Deenaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.

62. Mason MD, Clarke NW, James ND, Deenaley DP, Spears MR, Ritchie AWS, et al. Adding celecoxib with or without zoledronic acid for hormone-naive prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomised controlled trial. J Clin Oncol. 2017;35:1530–41.

63. Vale CL, Burdett S, Rydzewska LH, Albis L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17:243–56.

64. Deenaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009;10:872–6.

65. Deenaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, et al. A double-blind, placebo-controlled, randomised trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95:1300–11.

66. Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009;101:1949–56.

67. Di Lorenzo G, Tortora G, D’Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002;8:3438–44.

68. Day KC, Lorenzatti Hiles G, Kozminsly M, Dawsey SJ, Paul A, Broses LJ, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2017;77:74–85.

69. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA, et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107:289–98.

70. Dougall WC, Holen I, Gonzalez Suarez E. Targeting RANKL in metastasis. Bone Rep. 2014;3:519.

71. Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015;3:64–76.
Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer

72. Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005;96:985–9.

73. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17:S72–9.

74. Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, et al. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? Prostate Cancer Prostatic Dis. 2016;19:380–4.

75. Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015;68:42–50.

76. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68.

77. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.

78. Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;26:368–74.

79. von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Rader M, et al. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013;21:3497–507.

80. Coleman R. Treatment of metastatic bone disease and the emerging role of radium-223. Semin Nucl Med. 2016;46:99–104.

81. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Grant J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17:1306–16.

82. Nilsson S, Strang P, Aksnes AK, Fransen L, Olivier P, Pecking T, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.

83. Food and Drug Administration. ODAC briefing document: denosumab. 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM290400.pdf. Accessed Jan 2018.

84. Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;26:368–74.

85. von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Rader M, et al. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013;21:3497–507.

86. Coleman R. Treatment of metastatic bone disease and the emerging role of radium-223. Semin Nucl Med. 2016;46:99–104.

87. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Grant J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17:1306–16.

88. Nilsson S, Strang P, Aksnes AK, Fransen L, Olivier P, Pecking T, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.

89. Food and Drug Administration. ODAC briefing document: denosumab. 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM290400.pdf. Accessed Jan 2018.

90. Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;26:368–74.

91. von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Rader M, et al. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013;21:3497–507.

92. Body JJ, Von Moos R, Rider A, Bhowmik D, Hallworth P, Hechmati G, et al. Real-world treatment patterns and factors influencing the use of bone-targeted agents (BTAs) in combination with emerging therapeutics in patients with prostate cancer and bone-metastases. Eur Urol Suppl. 2016;15:Abstract 771.

93. Freedland SJ, Richrhiari A, Wang H, Chung K, Shore ND. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology. 2012;80:293–8.

94. Lebret T, Casas A, Cavo M, Woll PJ, Deleplace C, Kennedy C, et al. The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies—a European survey. Eur J Cancer Care. 2016;26. https://doi.org/10.1111/ecc.12490.

95. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15:36–44.

96. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038–42.

97. Body JJ, Terpos E, Tombil B, Hadji P, Arif A, Young A, et al. Bone health in the elderly cancer patient: a SIOG position paper. Cancer Treat Rev. 2016;51:46–53.

98. Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, et al. Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care—cancer care ontario clinical practice guideline. Clin Oncol. 2017;29:348–55.

99. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13:1210–17.

100. Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15:1147–56.

101. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, chemotherapy-naive metastatic castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15:1147–56.

102. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, et al. Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015;68:570–7.
103. Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios CH, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28:16–33.

104. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317:48–58.

105. Swiss Group for Clinical Cancer Research. Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks. NCT02051218. 2017. https://clinicaltrials.gov/ct2/show/NCT02051218. Accessed Oct 2017.

106. Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM, et al. Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2013;111:1301–9.

107. Hechmati G, Cure S, Gouepo A, Hoefeler H, Lorusso V, Luftner D, et al. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ. 2013;16:691–700.